Avacta to develop novel reagents to reduce use of animals in life sciences research

Yorkshire-based Avacta Group has been awarded a grant to work with the Mary Lyon Centre at MRC Harwell to develop novel Affimer reagents which could help reduce the use of animals in life sciences research.

Genetically engineered mice are a widely used and essential tool in biomedical research and drug development. If the efficiency of the mice breeding programmes could be improved, the cost of production would be reduced and fewer animals would be required, providing ethical as well as commercial benefits.

Dr Alastair Smith, Avacta Group CEO, said: “We are grateful to NC3Rs for providing the funding that will allow us to develop Affimer inhibitors of inhibin, which we will provide to MRC Harwell for evaluation. If successful then there is a potentially very large global market for such Affimer reagents that will reduce the costs of production and the number of mice used each year in breeding programmes. We are delighted to be working with MRC Harwell on this project which could also open the way to applications in human IVF treatments.”

Avacta has been awarded a CRACK IT Solutions technology partnering grant by NC3Rs, a UK-based scientific organisation dedicated to replacing, refining and reducing the use of animals in life sciences research. The grant provides funding for Avacta to develop Affimer inhibitors of a protein called inhibin. Inhibiting the action of this protein stimulates the production of greater numbers of embryos per mouse, a process called superovulation, which increases overall efficiency of a breeding programme. The Mary Lyon Centre at MRC Harwell, a world-leading centre for functional mouse genomics providing expertise, tools and facilities to generate mouse models of human disease, will evaluate the ability of the Affimer reagents to induce superovulation in mice.

A good inhibin inhibitor could reduce the number of mice needed for embryo production by 100,000 animals a year in the UK alone. When this is scaled up to the number of mice used in breeding programmes globally, there are substantial cost savings to be made in the production of genetically engineered mouse models as well as a significant reduction in animal use. The market for an Affimer reagent that induces superovulation in mice could therefore be substantial.


A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Related news

In brief: New head of R&D for Cellbox Solutions

Germany’s Cellbox Solutions has appointed Lonza Pharma and Biotech’s former Head of Biosolutions R&D as its new Head of R&D. Dr Herbert A. Mueller-Hartmann will...

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...